Molnár D, Dober H
Acta Paediatr Hung. 1985;26(2):139-45.
The effect of intravenous (IV) (10 ml of 10% calcium gluconate) and oral (3 g calcium) calcium on plasma immunoreactive insulin (IRI) and blood glucose levels was investigated during intravenous (0.5 g/kg bwt. glucose) and oral (1.75 g/kg bwt. glucose) glucose tolerance test in 21 control (body fat 14.0 +/- 0.5%) and 34 obese (body fat 36.1 +/- 0.7%) children. Calcium given before IV glucose tolerance test and IV or oral calcium by itself did not alter blood glucose and plasma IRI concentrations in either group. Oral calcium load significantly increased the glucose-induced IRI response and decreased the blood glucose levels in obese children with impaired glucose tolerance (n = 7) compared to the levels without calcium. Since IV calcium did not alter the plasma IRI concentration, it has been assumed that oral calcium exerts its effect by influencing the secretion of an insulin secretogogue gastrointestinal factor (gastric inhibitory polypeptide ?). This effect, however, was observed only in obese children with impaired glucose tolerance.
在21名对照儿童（体脂14.0±0.5%）和34名肥胖儿童（体脂36.1±0.7%）中，在静脉注射（0.5g/kg体重葡萄糖）和口服（1.75g/kg体重葡萄糖）葡萄糖耐量试验期间，研究了静脉注射（10ml 10%葡萄糖酸钙）和口服（3g钙）钙对血浆免疫反应性胰岛素（IRI）和血糖水平的影响。在静脉葡萄糖耐量试验前给予钙以及单独给予静脉或口服钙，两组的血糖和血浆IRI浓度均未改变。与未补钙时相比，口服钙负荷显著增加了糖耐量受损肥胖儿童（n = 7）中葡萄糖诱导的IRI反应，并降低了血糖水平。由于静脉注射钙未改变血浆IRI浓度，因此推测口服钙通过影响胰岛素分泌促进因子——一种胃肠因子（抑胃肽？）的分泌发挥作用。然而，这种作用仅在糖耐量受损的肥胖儿童中观察到。
